You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 4 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 4 findings. Do not include any additional text.

Abstract:
ABSTRACT.OBJECTIVE: We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1 study.

ABSTRACT.METHODS: Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16.

ABSTRACT.RESULTS: Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: −285 dyn s/cm5 (95% CI −357 to −213); p<0.0001) and persistent/recurrent (n=72; −131 dyn s/cm5 (95% CI −214 to −48); p=0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI −0.1 to 0.5; p=0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(−4.7 mm Hg (95% CI −6.9 to −2.6; p<0.0001 and −4.8 mm Hg (–8.2 to −1.5; p=0.0055), respectively). For all patients, changes in 6 min walk distance correlated with changes in PVR (r=−0.29 (95% CI −0.41 to −0.17); p<0.0001) and cardiac index (r=0.23 (95% CI 0.10 to 0.35); p=0.0004).

ABSTRACT.CONCLUSIONS: Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH.

ABSTRACT.TRIAL REGISTRATION NUMBER: NCT00855465.

Findings:
[["Riociguat group", "Placebo group", "Improvement of cardiac index in persistent/recurrent patients", "no significant difference", "Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p\u003c0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI \u22120.1 to 0.5; p=0.17)."], ["Riociguat group", "Placebo group", "Pulmonary vascular resistance", "significantly decreased", "Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: \u2212285 dyn s/cm5 (95% CI \u2212357 to \u2212213); p\u003c0.0001) and persistent/recurrent (n=72; \u2212131 dyn s/cm5 (95% CI \u2212214 to \u221248); p=0.0025) patients."], ["Riociguat group", "Placebo group", "Mean pulmonary artery pressure", "significantly decreased", "Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(\u22124.7 mm Hg (95% CI \u22126.9 to \u22122.6; p\u003c0.0001 and \u22124.8 mm Hg (\u20138.2 to \u22121.5; p=0.0055), respectively)"], ["Riociguat group", "Placebo group", "Improvement of cardiac index in inoperable patients", "significantly increased", "Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p\u003c0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI \u22120.1 to 0.5; p=0.17)."]]